Treatment with a PD-1 or PD-L1 inhibitor may be continued with close monitoring in patients with mild irAEs including hematological toxicities [16]; thus, early detection and prompt management for minimal interruption of cancer immunotherapy is critical to maintain the clinical benefits of PD-1 and PD-L1 inhibitors in real-world settings. The gene discussed is PDCD1; the disease is cancer.